Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Hypertens Res. 2014 Aug;37(8):724-32. doi: 10.1038/hr.2014.79. Epub 2014 Apr 10.
Chronic immunosuppressive therapy is often complicated by the development of both arterial hypertension and renal dysfunction. The principal aim of this study was to assess the effects of dual inhibition of renin-angiotensin system (RAS) and other antihypertensive treatment on blood pressure and renal function in normotensive and hypertensive Fawn-Hooded (FH) strains during chronic calcineurin inhibitor (CNI) administration. Combinations of perindopril (5 mg kg(-1) per day) and losartan (50 mg kg(-1) per day) or amlodipine (6 mg kg(-1) per day) and metoprolol (80 mg kg(-1) per day) were administered to normotensive (FHL) and hypertensive (FHH) rats, fed with diet containing tacrolimus (Tac; 12 mg kg(-1) per day). Tac-induced arterial hypertension in both animal strains (FHL: 151±4; FHH: 198±6 mm Hg) was prevented by dual RAS inhibition (FHL: 132±3 mm Hg, P<0.05; FHH: 153±3 mm Hg, P<0.05) as well as by a combination of amlodipine and metoprolol (FHL: 136±3 mm Hg, P<0.05; FHH: 166±4 mm Hg, P<0.05). However, significant nephroprotection was observed only in animals on dual RAS inhibition where albuminuria was reduced in both FHL (51.1±3.9 vs. 68.3±4.5 μg per day; P<0.05) and FHH rats (13.1±0.3 vs. 18.8±0.7 mg per day; P<0.05). We also found Tac-induced enhancement in renal angiotensin II activity that was significantly reduced by dual RAS inhibition in both FHL (63.5±3.2 vs. 23.1±3.0 fmol g(-1)) and FHH (79.8±8.5 vs. 32.2±5.8 fmol g(-1)). In addition, histological analysis revealed that RAS inhibition noticeably diminished glomerulosclerosis and tubulo-interstitial injury. This study indicates that dual blockade of RAS significantly attenuates Tac-induced arterial hypertension and nephrotoxicity in FH rats and further supports the notion that RAS inhibitors display efficient renoprotective properties during CNI treatment.
慢性免疫抑制治疗常因动脉高血压和肾功能障碍的发展而变得复杂。本研究的主要目的是评估肾素-血管紧张素系统(RAS)双重抑制和其他降压治疗对慢性钙调神经磷酸酶抑制剂(CNI)给药期间正常血压和高血压法恩霍德(FH)品系血压和肾功能的影响。培哚普利(5mg/kg/d)和氯沙坦(50mg/kg/d)或氨氯地平(6mg/kg/d)和酒石酸美托洛尔(80mg/kg/d)的组合分别给予正常血压(FHL)和高血压(FHH)大鼠,饮食中含有他克莫司(Tac;12mg/kg/d)。在两种动物品系(FHL:151±4;FHH:198±6mmHg)中,Tac 诱导的动脉高血压均被双重 RAS 抑制(FHL:132±3mmHg,P<0.05;FHH:153±3mmHg,P<0.05)以及氨氯地平和酒石酸美托洛尔的组合所预防(FHL:136±3mmHg,P<0.05;FHH:166±4mmHg,P<0.05)。然而,只有在接受双重 RAS 抑制的动物中才观察到显著的肾脏保护作用,其中 FHL(51.1±3.9 vs. 68.3±4.5μg/天;P<0.05)和 FHH 大鼠的白蛋白尿均减少(13.1±0.3 vs. 18.8±0.7mg/天;P<0.05)。我们还发现 Tac 诱导的肾血管紧张素 II 活性增强,这在 FHL(63.5±3.2 vs. 23.1±3.0fmol/g)和 FHH(79.8±8.5 vs. 32.2±5.8fmol/g)中均被双重 RAS 抑制显著降低。此外,组织学分析表明,RAS 抑制可显著减轻肾小球硬化和肾小管间质损伤。本研究表明,RAS 双重阻断可显著减轻 FH 大鼠 Tac 诱导的动脉高血压和肾毒性,并进一步支持 RAS 抑制剂在 CNI 治疗期间具有有效的肾脏保护作用的观点。